Heron Therapeutics (HRTX) Accumulated Expenses (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Accumulated Expenses data on file, last reported at $6.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 0.95% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 0.95% YoY) and the FY2025 annual result came in at $9.3 million, up 3811.39% from the prior year.
• Accumulated Expenses fell to $6.4 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.3 million in Q2 2022 to a low of $237000.0 in Q4 2024.
• A 5-year average of $9.0 million and a median of $8.7 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses tumbled 95.69% — and 2025, when it jumped 3811.39%.
• Tracing HRTX's Accumulated Expenses over 5 years: stood at $13.4 million in 2022, then tumbled by 59.01% to $5.5 million in 2023, then plunged by 95.69% to $237000.0 in 2024, then jumped by 3811.39% to $9.3 million in 2025, then tumbled by 31.07% to $6.4 million in 2026.
• The last three Accumulated Expenses figures came in at $6.4 million (Q1 2026), $9.3 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.